Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research

This article was originally published in PharmAsia News

Executive Summary

Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.

You may also be interested in...



AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research

Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.

Piramal Hopes Depth Of Neuraceq Data Will Provide Contrast For Third Alzheimer’s Imaging Agent

Neuraceq will be the third entrant into the beta-amyloid imaging market, a space already limited by concerns about the clinical utility of PET scans in Alzheimer’s disease management.

Alzheimer’s Conference Marked By Diversity Of Approaches

Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC087359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel